One current therapy is the BCL-2 inhibitor venetoclax (ABT-199), which unlike other targeted treatments in AML, like FLT3 or IDH1 inhibitors, can be used in a molecularly heterogeneous group of patients [68]. Here, BCL2 is linked to acute myeloid leukemia.